Incretin hormones exert pleiotropic metabolic actions beyond the pancreas. Although the heart expresses both incretin receptors, the cardiac biology of GIP receptor (GIPR) action remains incompletely understood. Here we show that GIPR agonism did not impair the response to cardiac ischemia. In contrast, genetic elimination of the Gipr reduced myocardial infarction (MI)-induced ventricular injury and enhanced survival associated with reduced hormone sensitive lipase (HSL) phosphorylation; it also increased myocardial triacylglycerol (TAG) stores. Conversely, direct GIPR agonism in the isolated heart reduced myocardial TAG stores and increased fatty acid oxidation. The cardioprotective phenotype in Gipr À/À mice was partially reversed by pharmacological activation or genetic overexpression of HSL. Selective Gipr inactivation in cardiomyocytes phenocopied Gipr À/À mice, resulting in improved survival and reduced adverse remodeling following experimental MI. Hence, the cardiomyocyte GIPR regulates fatty acid metabolism and the adaptive response to ischemic cardiac injury. These findings have translational relevance for developing GIPR-based therapeutics.
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In Brief
Ussher et al. demonstrate that the GIP receptor is expressed in cardiomyocytes and that direct activation of GIPR signaling regulates cardiac lipid metabolism. GIPR agonism was not deleterious in the context of ischemic cardiac injury; however, germline-or cardiomyocyte-selective loss of GIPR signaling increased survival and reduced adverse ventricular remodeling.
INTRODUCTION
Gut hormones are secreted in response to nutrient consumption and control gastrointestinal motility, nutrient digestion, absorption, and assimilation. The conserved glucoregulatory actions of glucagon-like peptide-1 receptor (GLP-1R) agonists and the favorable metabolic activity arising from inhibitors of dipeptidyl peptidase-4 (DPP-4) enabled the development of two new classes of incretin-based agents for the treatment of type 2 diabetes (T2D). The therapeutic importance of incretin therapies has been bolstered by the cardiovascular (CV) safety of DPP-4 inhibitors and by the reduced CV event rates shown for GLP-1R agonists (Drucker, 2016) . These findings, together with cardioprotective actions of SGLT-2 inhibitors (Kaul, 2017) , have increased interest in the cardiometabolic actions of investigational and established therapies for T2D and obesity.
There is now increased focus on the translational potential of next-generation metabolic therapies that improve GLP-1 action through addition of GIP receptor (GIPR) agonism (Tschö p et al., 2016) . GIPR agonists, GIP-GLP-1 co-agonists, and unimolecular triple agonists incorporating GIPR agonism all produced substantial reductions in blood glucose and body weight in preclinical studies (Finan et al., 2015) . Moreover, GIP-GLP-1 co-agonists reduced HbA1c and body weight in human subjects with T2D (Finan et al., 2013; Frias et al., 2017) . The relevance of GIPR signaling for human metabolism is further underscored by the association of genetic variation within the human GIPR with body mass index, b cell function, cerebrovascular disease, and the risk of T2D (Berglund et al., 2016; Finan et al., 2016) .
Although actions of glucagon and GLP-1 on the heart have been extensively studied, little is known about the cardiovascular biology of the GIPR. Here we show that GIPR agonism is not deleterious in normoglycemic mice with myocardial infarction (MI). Unexpectedly, Gipr À/À mice exhibited increased survival after sustained ischemic cardiac injury. Moreover, Gipr CMÀ/À mice with conditional inactivation of the Gipr in adult cardiomyocytes exhibited reduced infarct size and improved survival after MI. Furthermore, we demonstrate that GIPR signaling directly engages metabolic pathways controlling cardiac lipid metabolism. Collectively, these results reveal the biological importance of cardiomyocyte GIPR signaling in the context of ischemic cardiac injury. These findings have implications for development of GIP-based therapies for the treatment of metabolic disease. 
RESULTS
The Gipr Is Expressed in the Heart and Linked to Adenylate Cyclase Activation A full-length Gipr mRNA transcript was identified in all four chambers of the mouse heart ( Figure 1A ) as well as in mouse neonatal cardiac myocytes and HL-1 atrial myocytes (Figures S1A and S1B). Evaluation of three different commercially available GIPR antisera revealed that they were unsuitable (problems with sensitivity or specificity) for detection of the mouse GIPR ( Figure S1C ). Consistent with transcriptomics data localizing Gipr to mouse cardiomyocytes (Quaife-Ryan et al., 2017) , in situ hybridization identified a subset of Gipr-positive cardiac myocytes in the mouse ventricle and atrium ( Figure S1D ). GIPR mRNA transcripts were also detected in RNA from all four chambers of the human heart ( Figure S1E ). Moreover Gipr and Myl2 mRNA transcripts were enriched in RNA from adult mouse ventricular cardiac myocyte fractions, whereas Pecam1, Adgre1, and vimentin mRNAs were more abundant in the non-cardiomyocyte fraction ( Figure 1B ). Consistent with the canonical GIPR signaling pathway, activation of the GIPR in HL-1 atrial myocytes increased cAMP levels ( Figure 1C ).
Systemic GIPR Activation Does Not Modify the Outcome of Myocardial Ischemia-Induced Cardiac Injury
GIP stimulates insulin secretion and exhibits insulinomimetic activity, raising the possibility that GIP engages cardiac signal transduction through direct (cardiomyocyte GIPR), and indirect (insulin) mechanisms. Accordingly, we assessed myocardial insulin signaling pathways following peripheral administration of the degradation-resistant GIPR agonist [D-Ala 2 ]GIP (24 nmol/kg BW) or insulin (0.7 U/kg BW). [D-Ala 2 ]GIP increased Akt and glycogen synthase kinase 3b (GSK3b) phosphorylation in heart tissue from wild-type (WT) mice (Figures 1D and 1E) , associated with increased levels of circulating insulin ( Figure 1F ).
These cardiac actions of [D-Ala 2 ]GIP were extinguished in mice with b-cell-specific deletion of the Gipr (Gipr bcellÀ/À ) ( Figures   1G-1K ). Hence, interpretation of GIP action on the heart in vivo may be complicated by concomitant activation of cardiac signaling pathways through indirect (insulin-dependent) mechanisms.
We next studied GIPR activation in mice with permanent occlusion of the left anterior descending (LAD) coronary artery. One week pre-treatment with [D-Ala 2 ]GIP had no effect on mortality ( Figure 1L) ; however, ventricular weights, reflecting remodeling, trended higher, (p = 0.07), and left ventricle (LV) scar formation was increased in hearts from [D-Ala 2 ]GIP-treated mice ( Figures 1M-1O ).
Gipr -/-Mice Exhibit a Cardioprotective Response to Experimental Ischemia
We next determined whether loss of basal GIPR signaling impacts the response to ischemic cardiac injury. Gipr À/À mice with whole-body knockout of Gipr expression displayed normal cardiac function, heart rate, and structure in the basal state (Table S1 ). Unexpectedly, Gipr À/À mice exhibited improved survival ( Figure 1P ) and less adverse LV remodeling ( Figures  1Q-1S ) 4 weeks post-MI without changes in body weight (Figure 1T ). An intermediate level of improved survival was observed in Gipr +/À mice ( Figure 1P ). This cardioprotection was not associated with changes in Akt, GSK3b, or AMPK phosphorylation (Figures 2A-2C ). Although adipose triglyceride lipase (ATGL) protein expression was unchanged ( Figure 2D ), myocardial triacylglycerol (TAG) content was increased in Gipr À/À mice post-MI ( Figure 2E ), associated with decreased hormone-sensitive lipase (HSL) phosphorylation in viable Gipr À/À myocardium (Figures 2F and 2G) . Furthermore, mediators of myocardial injury-including macrophage inflammatory factor-1 (MIF-1), secreted protein acidic and rich in cysteine (SPARC), caveolin-1, and angiotensin-converting enzyme 2 (ACE2)-remained unchanged Figure 1 . Cardiac GIPR Expression and Action in the Normal and Ischemic Heart (A) Gipr expression in the mouse heart detected by RT-PCR; blot was hybridized with an oligonucleotide probe specific to the Gipr cDNA. Gipr mRNA transcripts were detected in all four heart chambers (left atria, LA; right atria, RA; left ventricle, LV; and right ventricle, RV). Epididymal white adipose tissue (WAT) and islet mRNA were used as controls.
(B) Real-time PCR demonstrating enrichment of Gipr and Myl2 mRNA transcripts in cardiac myocyte (CM) fractions versus Pecam1 (CD31), Adgre1 (F4/80), and vimentin that were more abundant in noncardiac myocyte (non-CM) fractions from adult mouse hearts (n = 4). (C) cAMP levels in HL-1 cells assessed 10 min after stimulation with [D-Ala 2 ]GIP (DA-GIP) (n = 5).
(D and E) Akt serine 473 phosphorylation (60 kDa) (D) and GSK3b serine 9 phosphorylation (46 kDa) (E) in hearts from overnight fasted mice treated with PBS or DA-GIP (24 nmol/kg body weight) for 1 hr (n = 4 or 5).
(F) Plasma insulin levels in overnight fasted mice treated with PBS, DA-GIP (24 nmol/kg body weight), or insulin (0.7 U/kg body weight) for 1 hr (n = 4 or 5).
(G) Gipr mRNA levels in islets from MIP-Cre and Gipr bcellÀ/À mice following 5 days of tamoxifen treatment (n = 4 or 5).
(H) Plasma insulin levels in overnight fasted MIP-Cre and Gipr bcellÀ/À mice treated with DA-GIP (24 nmol/kg body weight) (n = 4 or 5).
(I and J) Akt serine 473 phosphorylation (60 kDa) (I) and (J) GSK3b serine 9 phosphorylation (46 kDa) (J) in overnight fasted MIP-Cre and Gipr bcellÀ/À mice treated with DA-GIP (24 nmol/kg body weight) (n = 3-5).
(K) Representative images for western blot data quantified in (I) and (J).
(L) MI-induced mortality in PBS and DA-GIP-treated C57BL/6J mice (n = 19-21).
(M) Representative images depicting LV structure and infarct scar formation 2 weeks post-MI.
(N and O) Ventricular weight:body weight (VW/BW) ratios (n = 9 or 10) (N) and LV infarct scar formation (O) in PBS and DA-GIP treated C57BL/6J mice (n = 7 or 8).
(P) Mortality in Gipr
, and Gipr À/À mice subjected to permanent LAD coronary artery occlusion (n = 16-32).
(Q) Representative images depicting LV structure and scar formation 4 weeks post-MI. (R and S) Ventricular weight:body weight (VW/BW) ratios (n = 5-12) (R) and LV infarct scar formation (S) in Gipr +/+ and Gipr À/À mice (n = 7 or 8).
(T) Body weights in Gipr +/+ and Gipr À/À mice pre-and post-permanent LAD coronary artery occlusion surgery (n = 9-12).
Values represent mean ± SE. Differences were determined using a Kaplan Meier survival analysis, an unpaired Student's two-tailed t test, or a 1-way or 2-way ANOVA followed by a Bonferroni post hoc analysis. hearts ( Figure 2L ) in association with a reduction in HSL phosphorylation and ATGL protein expression in Gipr À/À hearts (Figures 2M and 2N) . We next examined whether GIPR signaling in the heart directly controls TAG/fatty acid metabolism by perfusing working mouse hearts aerobically with either vehicle or [D-Ala 2 ]GIP. GIPR activation had no effect on myocardial glucose oxidation, but it increased fatty acid oxidation rates (Figures 2O and 2P) . Moreover, the GIP antagonist GIP(3-30) (Sparre-Ulrich et al., 2017) , which attenuated GIP-stimulated insulin secretion in islets (Figure 2Q) , completely abrogated the increase in myocardial fatty acid oxidation rates ( Figure 2P ).
GIPR Deficiency Does Not Confer Protection against
Experimental Heart Failure Despite exhibiting robust protection against ischemic cardiac injury, Gipr À/À mice did not exhibit improved survival in response to doxorubicin-induced cardiac toxicity ( Figure S2A ), though cardiac atrophy was attenuated ( Figures S2B and S2C ) and myocardial HSL phosphorylation was unaltered ( Figure S2D ). Similarly, LV function was not improved in Gipr À/À mice following transverse aortic-constriction-induced heart failure (Figures S2E and S2F) . Hence, the cardioprotection elicited by reduced cardiac GIPR activity appears specific to the context of ischemic injury. Figure 3C ), whereas a $60% siRNA-mediated reduction of HSL protein expression in HL-1 cells ( Figure 3D ) attenuated the [D-Ala 2 ]GIP-mediated decrease in intracellular TAG content ( Figure 3E ).
GIPR

GIP-Induced HSL Phosphorylation Depends on Protein
Kinase G/Extracellular-Signal-Regulated Kinase (ERK) Activity The GIPR-mediated increase in HSL phosphorylation in HL-1 cardiac myocytes was not prevented by the protein kinase A inhibitor H89, the cAMP antagonist Rp-cAMP ( Figure S2G ), or the p38 MAPK inhibitor SB203580 ( Figure S2H ). Forskolin increased HSL phosphorylation, which was blocked by H-89; however Epac2 activation with ESCA-AM did not enhance HSL phosphorylation ( Figure S2I ). Figures S2L and S2M) . The protein kinase G (PKG) activator 8-Br-cGMP increased ERK ( Figure S3A ) and HSL ( Figure S3B ) phosphorylation in a temporal pattern mimicking that seen following GIPR activation. Furthermore, pretreatment with U0126 abolished the 8-Br-cGMP-induced increase in ERK and HSL phosphorylation and the subsequent decrease in intracellular TAG content ( Figures S3C and S3D Values represent mean ± SE. Differences were determined using an unpaired Student's two-tailed t test or a 1-way or 2-way ANOVA followed by (legend continued on next page) distribution; it is predominantly restricted to cardiomyocytes, skeletal muscle, the urinary bladder, and adipose tissue. Administration of the selective b 3 adrenoceptor agonist ZD 7114 (10 mg/kg i.p.) increased myocardial HSL phosphorylation in WT mice 6 hr post-treatment ( Figure S3I ). ZD 7114 had no effect on ischemia-induced mortality following LAD coronary artery occlusion in Gipr +/+ mice ( Figure 3F ). In contrast, ZD 7114 treatment increased mortality in Gipr À/À mice following LAD coronary artery occlusion ( Figure 3G ) in the absence of changes in body weight ( Figure S3J ) and independent of any changes in ischemia-induced adverse LV remodeling ( Figures 3H-3J Table S1 ). Furthermore, LV infarct scar formation was no longer reduced in Gipr Cardiomyocyte-Selective Inactivation of the Gipr Attenuates Ischemia-Induced Mortality and Adverse LV Remodeling We next assessed Gipr expression in right and left ventricles and the LV infarct zone after induction of MI. Remarkably, levels of Gipr mRNA transcripts were robustly yet transiently induced in the LV infarct zone by 12 and 24 hr after coronary artery ligation, returning to control levels by 48 hr ( Figure 4A ). To elucidate whether cardioprotection in Gipr À/À mice reflects selective GIPR deficiency in the myocardium, we conditionally inactivated the Gipr in adult mouse cardiomyocytes (Gipr CMÀ/À ). Cardiac Gipr mRNA expression was reduced by $90%, with no changes in levels of Gipr mRNA in pancreas or white adipose tissue ( Figure 4B ). Strikingly, Gipr CMÀ/À mice exhibited enhanced survival and reduced adverse LV remodeling following LAD coronary artery occlusion ( Figures  4C-4F ). Consistent with observations in Gipr À/À mice, Gipr CMÀ/À mice also exhibited increased myocardial TAG content 48 hr post-MI ( Figure 4G ). Moreover, HSL phosphorylation was decreased in the viable myocardium 48 hr post-MI in Gipr CMÀ/À mice, reflecting a reduction in HSL protein expression ( Figures 4H-4L ). Collectively, findings in Gipr CMÀ/À mice substantially phenocopy the cardioprotective phenotype arising in whole-body Gipr À/À mice, revealing a role for the cardiomyocyte GIPR in the response to ischemic cardiac injury.
DISCUSSION
Proglucagon-derived peptides-specifically, glucagon, GLP-1, and GLP-2-exert important actions in the control of energy metabolism, and their receptors represent validated targets for the treatment of metabolic and intestinal disease. Notably, activation of the GLP-1R is broadly cardioprotective in preclinical studies, and several GLP-1R agonists reduced the development of cardiovascular events, including rates of MI, in human subjects with T2D (Drucker, 2016; Kaul, 2017) . Surprisingly, however, the available data localizes GLP-1R expression predominantly to the atrium-specifically, the sinoatrial node (Kim et al., 2013; Pyke et al., 2014) . Hence, the mechanisms linking GLP-1R signaling to ventricular function and cardioprotection remain incompletely understood. Although less extensively studied, the incretin hormone GIP and its receptor, GIPR, represent important components of a gut-islet axis controlling glucose homeostasis. GIP, together with GLP-1, mediates the glucoregulatory actions of DPP-4 inhibitors (Hansotia et al., 2004) , medicines widely used to treat T2D. Clinical observations demonstrating restoration of glucoregulatory responses to GIP following a brief period of improved glucose control in human subjects with T2D (Højberg et al., 2009) have boosted enthusiasm for the therapeutic potential of GIPR agonism. Coagonists targeting the GIPR are under clinical investigation for the treatment of T2D (Finan et al., 2013; Frias et al., 2017) , and daily administration of a unimolecular acylated GIP/GLP-1 dual agonist reduced HbA1c, cholesterol, and body weight over 12 weeks in metformin-treated subjects (Frias et al., 2017) .
The efficacy of GIPR antagonism or reduction of GIP secretion for the treatment of obesity and its complications is also being explored (Campbell and Drucker, 2013; Finan et al., 2016) . Genetic reduction of GIP secretion reduced adipose tissue mass and decreased body weight gain in high-fat-fed mice (Nasteska et al., 2014) . Notably, acute GIPR antagonism reduced C-peptide levels and decreased adipose tissue uptake of fatty acids and triglyceride deposition in humans (Asmar et al., 2017) , consistent with the hypothesis that sustained GIPR antagonism may prevent accretion of adipose tissue. Here we highlight a role for GIP action in the cardiovascular system, supported by demonstration that the GIPR gene is expressed in both the mouse and human heart. In contrast to the predominantly atrial expression of the Glp1r (Kim et al., 2013; Pyke et al., 2014; Quaife-Ryan et al., 2017) , Gipr mRNA transcripts are detectable within ventricular myocytes. Moreover, expression of the mouse cardiac GIPR is transiently induced following ischemic cardiac injury, and functionally linked to control of lipid metabolism.
Physiologically, GIPR signaling also controlled HSL phosphorylation and myocardial TAG metabolism during meal intake. Moreover, we observed a GIPR-mediated reduction of TAG content in the isolated working heart ( Figure S3M ), and using radiolabeled tracers to measure myocardial metabolism, we Values represent mean ± SE. Differences were determined using a Kaplan Meier survival analysis, an unpaired Student's two-tailed t test, or a 1-way or 2-way ANOVA followed by a Bonferroni post hoc analysis. *p < 0.05, significantly different from PBS, si-Con, or VC-treated counterpart; # p < 0. demonstrated that GIPR activation increases myocardial fatty acid oxidation rates. Our isolated working heart perfusions involved a 45-min equilibration period in order to saturate the TAG pool with radiolabeled palmitate. Hence, the decreased TAG content combined with a similar percentage of radiolabeled palmitate within the TAG pool 35 min post-GIPR activation ( Figure S3N ) suggests that GIPR activation in the heart is likely increasing both endogenous and exogenous fatty acid oxidation. Since previous studies have demonstrated that virtually all palmitate released within endogenous TAGs is oxidized via the isolated working heart, which is necessary to fuel the heart's enormous metabolic demand (Lopaschuk et al., 2010), it is unlikely that the TAG-released palmitate following cardiac GIPR activation would be liberated into the perfusate. Importantly, the cardioprotective phenotype arising in wholebody Gipr À/À mice was substantially reproduced by selective inactivation of the cardiomyocyte Gipr. Hence, reduction of cardiac GIPR activity represents a potential strategy for preservation of vulnerable myocardium in the context of ischemic heart disease. GIP is known to enhance lipoprotein lipase and HSL activity in adipocytes (Asmar et al., 2017; Eckel et al., 1979; Timper et al., 2013) , and GIP administration acutely enhanced pancreatic lipase activity in rats in vivo (Duan and Values represent mean ± SE. Differences were determined using a Kaplan Meier survival analysis, an unpaired Student's two-tailed t test, or a 1-way ANOVA followed by a Bonferroni post hoc analysis. # p < 0.05, significantly different from LV at time 0; y p < 0.05, significantly different from RV and LV 24 hr post LAD; *p < 0.05, significantly different from aMHC-Cre mice. Erlanson-Albertsson, 1992 ). Here we extend these metabolic findings by demonstrating that gain and loss of GIPR signaling controls cardiac HSL activity. Hence, refeeding-associated increases in plasma GIP levels activate myocardial HSL to allow mobilization of endogenous TAG stores for energy metabolism, which may contribute to endogenous myocardial TAG stores accounting for $25% of myocardial energy metabolism in humans subjected to hyperglycemia (Wisneski et al., 1990) . Notably, the ischemia-associated increase in cardiac HSL phosphorylation was attenuated in Gipr Taken together, our findings illustrate that reduction of cardiac GIPR expression is linked to impaired HSL-mediated control of TAG metabolism and marked cardioprotection against ischemic-induced myocardial injury. In contrast, GIPR agonism in the context of experimental ischemia was not associated with maladaptive cardiac responses or changes in survival. These findings inform the preclinical safety of GIPR agonism for the treatment of metabolic disease (Finan et al., 2013; Frias et al., 2017; Tschö p et al., 2016) . The increasing interest in development of metabolic therapies that enhance GIP action (Campbell and Drucker, 2013; Finan et al., 2016) , together with ongoing efforts to develop GIP receptor antagonists for the treatment of obesity, highlight the translational implications of the current findings. Our data reveals an entirely new aspect of GIP action in the heart, suggesting that attenuation of GIPR signaling in cardiomyocytes merits exploration as a potential strategy to mitigate ischemic cardiac injury.
Study Limitations
The striking cardioprotective phenotype evident in Gipr À/À , Gipr +/À , and Gipr CMÀ/À mice strongly links reduction of cardiomyocyte GIPR signaling to attenuation of ischemic injury and adverse LV remodeling within the context of the cardiac ischemia model studied herein.
Nevertheless, these experiments have several limitations. The current studies characterizing the cardiac actions of the GIPR are confined to chronic ischemic-injury-induced heart failure and adverse LV remodeling, and it will be important to determine whether such actions are conserved in the setting of acute MI and transient ischemia/reperfusion (I/R) injury. Furthermore, ventricular remodeling was examined 4 weeks after ischemic injury in the current studies, and it will be useful to understand the impact ensuing from loss of cardiac GIPR signaling on remodeling at more chronic time points several months after myocardial infarction. Of interest, myocardial fatty acid oxidation rates are increased in subjects with obesity or diabetes and associated with poor cardiac recovery during I/R injury (Lopaschuk et al., 2010) . As circulating GIP levels are increased in obesity (Jones et al., 1989) , it is possible that increased cardiac GIPR signaling contributes to the elevated fatty acid oxidation rates and lipotoxicity associated with obesity-related cardiomyopathy and may exacerbate I/R injury in such scenarios. Moreover, whether reduced cardiac GIPR signaling influences the extent and consequences arising from MI within hours to days following LAD coronary artery occlusion requires investigation. Because we did not perform serial assessments of cardiac function post-MI for prolonged periods of time, we are precluded from understanding the chronic dynamic consequences of manipulating GIPR signaling in the setting of experimental MI. Our findings linking reduction of GIPR signaling to ischemic cardioprotection advance our understanding of incretin biology in the heart and raise new questions surrounding the cardiovascular importance of GIPR signaling in the normal and diseased heart.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Animal Husbandry All procedures were conducted according to protocols and guidelines approved by the Toronto Centre for Phenogenomics (TCP) Animal Care Committee. Experiments were conducted in male mice acclimatized to handling and housed under a 12-h light/dark cycle with free access to standard rodent diet (2018, 18% kcal from fat; Harlan Teklad, Mississauga, ON, Canada) and water, unless otherwise noted. C57BL/6J mice were obtained from an internal TCP colony. The generation and characterization of Gipr À/À mice has been described previously (Miyawaki et al., 1999 Campbell et al., 2016) . Cre-induced inactivation of the Gipr gene was carried out via 6 intraperitoneal (i.p.) injections of tamoxifen (50 mg/kg) over 8 days (Ussher et al., 2014) . To minimize effects from transient, reversible cardiomyopathy (Koitabashi et al., 2009 ), mice were allowed 5 weeks to recover before experimentation. All mice were 10-12 weeks of age prior to experimentation, and all mice were housed at room temperature. Expanded information on animal characteristics is provided in the Method Details below.
Human Cardiac RNA RNA was prepared from all 4 chambers of 15 different human heart samples obtained from the University of Pennsylvania Heart BioBank, via Dr. Ken Margulies. Tissues from failing human hearts were obtained from male patients receiving heart transplantation at the University of Pennsylvania. The use of human heart tissue for research was approved by the University of Pennsylvania's Institutional Review Board. Non-failing heart tissue was obtained from deceased organ donors through the Gift-of-Life donor program in Philadelphia. Prospective informed consent for research use of heart tissue was obtained from all transplant recipients and from the appropriate next of kin for the organ donors. All human tissues received in situ high-potassium cardioplegia at the time of tissue procurement and were kept on wet ice for less than four hours before fixation in freshly prepared paraformaldehyde. Further details on patient characteristics are described in Table S2 .
Culturing of HL-1 Cells
The HL-1 cell line was established from an AT-1 tumor excised from subcutaneous tissue from a female adult C57BL/6J mouse originating from the Jackson Laboratory (Claycomb et al., 1998) . HL-1 cells were cultured in Claycomb media (Sigma) as previously described (Ali et al., 2014) . Prior to all drug treatments, cells were serum starved in serum-free high glucose Dulbecco's Modified Eagle's Medium (DMEM, Sigma) containing 1% penicillin/streptomycin for 3 hr. To determine intracellular TAG content, cells were lipid loaded overnight with serum-free Claycomb media containing 0.4 mM oleic acid (Sigma) bound to 2% bovine serum albumin (BSA), followed by media change to serum-free Claycomb media without oleic acid and treatment with various drugs/peptides. All drugs and inhibitors including ZD 7114 were purchased from Sigma, whereas D-Ala 2 GIP was purchased from Chi Scientific.
METHOD DETAILS Permanent Left Anterior Descending (LAD) Coronary Artery Occlusion
Experimental myocardial infarction (MI) was induced via permanent ligation of the left anterior descending (LAD) coronary artery in 10-12-week-old male Gipr À/À mice and their Gipr +/+ littermates, 10-12-week-old male Gipr À/À :MHC-Lipe mice, or 10-12-week-old male Gipr CMÀ/À mice and their aMHC-Cre littermates as previously described (Noyan-Ashraf et al., 2009 ). Sham-operated mice underwent the same procedure by moving the suture underneath the LAD coronary artery but without tying off the vessel. The surgeon was blinded to the genotypes of all mice for all surgeries. During post-operation recovery, mice were returned to their cages, which were placed on a heating pad for $2 hr to assist mice in maintaining body temperature prior to animals being returned to their appropriate animal housing within the TCP. Cardiac examinations were performed on all deceased mice. The presence of a large amount of blood or clot around the heart and in the thoracic cavity, in addition to a perforation of the infarct or peri-infarct area was indicative of cardiac rupture.
Experimental Cardiomyopathy
Experimental cardiomyopathy was induced via single i.p. injection of the anticancer anthracycline (drug class made from the bacteria Streptomyces peucetius) agent doxorubicin (20 mg/kg) in Gipr À/À mice and their Gipr +/+ littermates as previously described (Neilan et al., 2007) . Mice were followed for 10 days and hearts from surviving mice underwent histological assessment, or analysis of protein expression.
Transverse Aortic Constriction (TAC) Surgery
In order to induce pressure-overload hypertrophy, an oblique 8-mm incision was made 2 mm away from the left sternal border and the transverse aortic arch was banded between the innominate artery and the left common carotide artery with a 28 gauge needle using a 7-0 silk suture in Gipr À/À mice and their Gipr +/+ littermates as previously described (Mulvihill et al., 2016) . Sham-operated mice underwent the same procedure by moving the suture behind the transverse aortic arch but without tying it off. The surgeon was blinded to the genotypes of all mice for all surgeries. During post-operation recovery, mice were returned to their cages, which were placed on a heating pad for $2 hr to assist mice in maintaining body temperature prior to animals being returned to their appropriate animal housing within the TCP.
Ultrasound Echocardiography
Transthoracic echocardiography ultrasound was performed in 3% isoflurane-anesthetized mice (30-40 MHz; Vevo770, VisualSonics,Toronto, Canada) that had their body temperature maintained and continually monitored/recorded on a heating device, for the assessment of LV function and LV wall structure pre-surgery and post-surgery (MI and TAC), as previously described (Mulvihill et al., 2016) . The operator was blinded to the genotypes of all mice for these ultrasound experiments.
Treatment with GIPR agonists
In subsets of experiments involving the assessment of systemic GIPR agonism of myocardial signaling, groups of mice were treated with D-Ala 2 GIP (24 nmol/kg BW) immediately after an overnight fast and hearts were extracted 1 hr post-treatment. To assess consequences of GIPR activation before induction of ischemia, D-Ala 2 GIP (24 nmol/kg BW) was administered twice daily for 1 week before experimental MI. All injections took place between 7:00 -8:00 am and 4:00 -5:00 pm.
Isolated Working Heart Perfusions and Assessment of Energy Metabolism
Mice were anaesthetized with sodium pentobarbital (60 mg/kg IP), and the hearts were subsequently excised and immersed in icecold Krebs-Henseleit bicarbonate solution, following which the aorta was cannulated and equilibrated in the Langendorff mode. From here, the left atria was subsequently cannulated, allowing hearts to receive perfusate through the left atrium that enters the left ventricle and is subsequently ejected through the aorta during working mode perfusion as previously described (Gopal et al. C]glucose was delivered to the left atrium at a preload pressure of 15 mmHg, while perfusate was ejected from hearts into the aortic outflow line against a hydrostatic afterload pressure of 50 mmHg. Hearts were perfused aerobically for 80 min and glucose and palmitate oxidation were assessed as previously described (Gopal et al., 2017; Ussher et al., 2009) . At the end of perfusion, hearts were immediately frozen in liquid N 2 with Wollenberger tongs, and stored at À80 C.
Histology and Assessment of Left Ventricle (LV) Infarct Scar Formation
Animals were anesthetized using avertin (250 mg/kg i.p. injection). The chest was opened and an apical injection of 1 M KCl arrested the heart in diastole. Hearts were perfusion-fixed with 4% buffered formalin at physiological pressure, post-fixed in formalin, embedded in paraffin, sectioned at 6 mm, and stained with Masson's Trichrome or hematoxylin and eosin (H&E). Cardiac morphometry was performed with Aperio ImageScope Viewer software (Aperio Technologies) using digital planimetry to quantify the 2-dimensional area/region of infarcted scar from LV cross sections of high resolution digital photographs (Noyan-Ashraf et al., 2009; Sauvé et al., 2010) . Infarcted/scarred LV area was calculated as a % of total LV area and the analysis was not blinded. Cardiac hypertrophy was quantified as the ventricular weight-to-body weight ratio.
Triacylglycerol (TAG) Determination
TAGs were extracted from frozen ventricular tissue or cell pellets (20 -30 mg) with a 2:1 chloroform-methanol solution and quantified with a commercially available enzymatic assay kit (Wako Pure Chemical Industries) as previously described (Ussher et al., 2009 ).
Isolation of Adult Cardiomyocyte and Non-Cardiomyocyte Fractions
Cardiomyocyte and non-cardiomyocyte fractions were prepared from adult mouse ventricles as described (O'Connell et al., 2007) with the following modifications: 1) Ventricles were digested using 1.5 mg/ml collagenase II (Worthington Biochemicals, Lakewood, NJ; Cat# LS004176), and 2) Following sedimentation of isolated cardiomyocytes via centrifugation at 20 g for 3 min, the supernatant was collected and centrifuged at 300 g for 5 min to pellet non-cardiomyocytes.
Culturing of HEK293 Cells and Transient Transfection for Determining GIPR Antibody Specificity HEK293 cell lysates were prepared by homogenization in phosphate buffered saline supplemented with 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate and protease inhibitor cocktail (Sigma-Aldrich, Oakville, Ontario, Canada). Lysates were cleared by centrifugation and then treated for 1 hr at 37 C with sample buffer containing b-mercaptoethanol. 40 mg of protein were resolved by discontinuous SDS-PAGE and then electrotransferred onto Amersham Protran nitrocellulose membrane (GE Healthcare Life Sciences, Mississauga ON Canada) using standard procedures. Blots were probed at room temperature with antibodies diluted in 5% skim milk in Tris buffered saline containing 0.2% Tween-20. Antigen-antibody complexes were visualized with a secondary antibody conjugated to horseradish peroxidase and an enhanced chemiluminescence kit (Perkin Elmer). Chemiluminescence detection was performed on a Kodak Imager. The following rabbit polyclonal antibodies to the GIP receptor were used, all at a dilution of 1:500: A9816 (ABclonal, Woburn MA), NLS1251 (Novus Biologicals, Oakville ON Canada), and ab198694 (Abcam, Cambridge, MA). The rabbit polyclonal anti-FLAG antibody (cat# 2368, 1:2500 dilution) was from Cell Signaling Technology (Whitby ON Canada). Transient transfection of HEK293 cells with the murine GIP receptor cloned into the pFLAG-CMV-5b vector (GipR-FLAG; Sigma, St. Louis, MO) (Harada et al., 2008) was done using Lipofectamine 2000 reagent (Invitrogen Life Technologies, Thermo Fisher Scientific) according to the manufacturer's protocol.
Detection of Full Length Mouse Gipr mRNA Total RNA was isolated using TRIzol reagent (Sigma). 2 mg total RNA was reversed transcribed at 50 C for 60 min using Superscript III reverse transcriptase and random hexamer primers (Sigma). The mouse GIPR was amplified by PCR using primer pairs 5 0 -CTG CTT CTG CTG CTG TGG T-3 0 and 5 0 -CAC ATG CAG CAT CCC AGA-3 0 . Amplification of mouse GIPR cDNA resulted in generation of an approximately 1.5-kb product spanning bases 79-1486 of the GIPR open reading frame. After gel electrophoresis and transfer to nylon membranes, blots were hybridized with a 32 P-labeled mouse (5 0 -GCTGTATCTGAGCATAGGCT-3 0 ) GIPR oligonucleotide probe overnight. After washing, blots were exposed to a phosphorimaging cassette and visualized using a Storm 860 Phosphor Screen and analyzed with Quantity One imaging software (Bio-Rad).
Detection of GIPR mRNA Expression in Human Heart
Human tissues from all 4 heart chambers (left atria, right atria, left ventricle, right ventricle) were pulverized in liquid nitrogen. Total RNA was extracted using Tri Reagent (Molecular Research Center Inc., Cincinnati, OH). cDNA was synthesized from 1 mg of DNase I-treated (Thermo-Fisher Scientific) total RNA using random hexamers and Superscript III (Thermo-Fisher Scientific). A 1.35 kb PCR product encompassing the majority of the human GIPR coding region was amplified from cDNA using the primer pairs 5 0 -TGA CTA CCT CTC CGA TCC TG-3 0 and 5 0 -AGG GTC CCC GAG GAC AAG-3.' PCR products were separated on agarose gels, transferred to nylon membranes and hybridized with an internal human GIPR-specific 32 P-labeled oligonucleotide probe (5 0 -CTC CTG TCC AAG CTG AGG AC-3 0 ). Blots were exposed to a Storm 860 Phosphor Screen and visualized using Quantity One imaging software (Bio-Rad).
In Situ Hybridization
For in situ hybridization, mouse hearts were formalin-fixed for 24 hr, embedded in paraffin, cut into 5 mm sections and mounted onto Superfrost Plus (Thermo-Fisher Scientific) glass slides. In situ hybridization for mouse Gipr was performed using the RNAscope 2.5 HD Detection Reagent kit (Advanced Cell Diagnostics Inc.) and mouse Gipr specific hybridization probes Mm-Gipr-01 and Mm-Gipr-02 (Cat# 455781 and 455791, respectively; Advanced Cell Diagnostics Inc.) according to the manufacturer's instructions. Slides were scanned at 40X and imaged using Aperio Image Scope v11.2.0.780 software (Leica Biosystems Imaging Inc.).
Cyclic AMP (cAMP) Assay cAMP levels were quantified in HL-1 cells cultured in 24-well plates and treated with various concentrations of [D-Ala 2 ]GIP using a radioimmunoassay kit as previously described (Bates et al., 2012) . This kit utilizes a highly immunoreactive [I 125 ]S-cyclic AMP-tyrosyl methyl ester with specific primary antibodies conjugated to secondary antibodies, thereby minimizing non-specific binding and requiring only one incubation step.
Real Time Quantitative PCR First-strand cDNA was synthesized from total RNA of myocardial extracts using the SuperScript III synthesis system (Invitrogen, Carlsbad, CA). Real time PCR was carried out with the ABI Prism 7900 Sequence Detection System using TaqMan Gene Expression Assays (Applied Biosystems, Foster City, CA). Relative changes in mRNA transcript levels between experimental groups were quantified with the 2 -DDCt method as previously described (Livak and Schmittgen, 2001) , which assumes that the amplification efficiencies of the target and internal control genes are near identical. For our purposes cyclophilin was chosen as a house keeping internal control gene, as it was not affected by our experimental manipulations or by genotype in our studies.
Islet Isolation, Perifusion and Analysis of GIP(3-30)
Islets were isolated from WT mice and perifused for 1 hr in Krebs-Ringer bicarbonate buffer with 2.7 mM glucose at a flow rate of 200 mL per min using the Biorep Perifusion system as previously described (Campbell et al., 2016) . Insulin secretion was assessed in response to 10 mM glucose, 10 mM glucose plus 1 nM DA-GIP, and 10 mM glucose plus 1 nM DA-GIP and 1 uM . Insulin values were determined by AlphaLISA assay (Perkin Elmer), following the manufactures instructions. The AUC was calculated for each condition, and the AUC for high-glucose alone was subtracted from the DA-GIP and DA-GIP+GIP(3-30) values. Data was then expressed as a percentage of DA-GIP to determine the percentage suppression by GIP(3-30).
Immunoblot Analysis
Frozen ventricular tissue (20 mg) was homogenized and HL-1 cells lysed in buffer containing 50 mM Tris HCl (pH 8 at 4 C), 1 mM EDTA, 10% glycerol (wt/vol), 0.02% Brij-35 (wt/vol), 1 mM dithiothreitol, protease and phosphatase inhibitors (Sigma) as previously described (Ussher et al., 2012) . Protein concentration of homogenates was determined via Bradford protein assay kit (Bio-Rad). Samples were resolved via 8% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto a 0.20 mm nitrocellulose membrane. Membranes were blocked with 10% fat free milk for 2 hours and probed with either anti-HSL ( A gel-documentation imager was used to visualize images detected by the secondary antibody bound to the primary antibody following emission of chemiluminescence (Perkin Elmer). As the molecular markers on the nitrocellulose membrane do not emit chemiluminescence, they do not appear on corresponding acquired image. Therefore, after image exposure, the nitrocellulose membrane itself was photographed, and the gel-doc-acquired image was subsequently overlayed on the nitrocellulose membrane image. The migration positions of the detected protein bands were then directly compared to the molecular markers from the protein ladder, to verify that individual protein bands corresponded to the expected molecular size based on the literature and the manufacturer's specifications (e.g., Phospho-Akt from Cell Signaling (9271) appearing at $60 kDa). The molecular weights indicated for all proteins quantified by western blot analysis in our Figure Legends were determined in this specific manner.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical Analysis
All values are presented as mean ± SE (n observations). The significance of differences was determined by a Kaplan Meier survival analysis, an unpaired, 2-tailed Student's t test, two-way analysis of variance (ANOVA), or a one-way ANOVA followed by a Bonferroni post hoc analysis where appropriate. One-way ANOVA was performed when there were 3 or more experimental groups with one experimental outcome being measured (e.g., cAMP levels in response to various concentrations of [D-Ala 2 ]GIP). Conversely, twoway ANOVA was performed whenever an experimental outcome being measured was influenced by two experimental variables (e.g., cardiac TAG content in WT and Gipr À/À mice in response to either a 24 hr fast or a 24 hr fast-2 hr refeed). Differences were considered significant when p < 0.05. All statistical parameters can be found in the figure legends. A: Gipr mRNA expression was detected in neonatal cardiac myocytes (NCMs) and B:
HL-1 atrial cardiac myocytes by RT-PCR and blotting of PCR products followed by hybridization with an internal oligonucleotide probe specific to the mouse full length Gipr cDNA. C: Immunoblots characterizing the putative specificity of commercial GIPR antibodies using protein extracts from liver and heart of Gipr . N: The percent of radiolabeled palmitate within the myocardial TAG pool at the end of the isolated working heart perfusion (n = 4).Values represent mean ± SE. Differences were determined using an unpaired Student's two-tailed t-test or a 2-way ANOVA followed by a Bonferroni post-hoc analysis. *P<0.05, significantly different from PBS counterpart. samples were obtained from male, Caucasian patients. Afib, atrial fibrillation; BMI, body mass index; BSA, blood serum albumin; C, cardiomyopathy; CHF, chronic heart failure; HW; heart weight; ID-CMP, idiopathic cardiomyopathy; LV, left ventricle; LVEF, left ventricular ejection fraction; N, no; NF, non-failing; VT/VF, ventricular tachycardia/ventricular fibrillation; U, unknown; Y, yes.
